甲状腺相关眼病伴眼压升高是否需要降眼压治疗
本文分析甲状腺相关眼病(TAO)伴眼压升高的可能机制,包括眼外肌肥大水肿压迫眼球壁、眶内结缔组织及眼肌肥大水肿使眶压增加导致房水静脉压升高和房水流出阻力增加等,并指出眼位和测量仪器影响眼压测量精准度。作者提出应针对TAO的临床表现和特点制定不同的治疗策略,多数患者通过积极治疗TAO可使眼压降低,眼压无法降低者可考虑抗青光眼药物治疗,仅极少数青光眼病例需要抗青光眼药物或手术。
要点
- TAO高眼压机制包括眼外肌压迫、眶压升高致房水静脉压升高及房水流出阻力增加。
- 眼位和测量仪器对眼压测量精准度有较大影响。
- 应针对TAO临床表现制定不同治疗策略,多数患者积极治疗TAO后眼压可降低。
核心结论
- TAO高眼压是否需要降眼压治疗取决于TAO的具体临床表现。
- 多数患者通过积极治疗TAO可使眼压降低;眼压无法降低者可能需要抗青光眼药物治疗;仅极少数青光眼病例需要抗青光眼药物或手术。
研究设计与样本
- 本文为发表于《中华眼科杂志》2019年第55卷811-813页的论述性文章,分析TAO高眼压的发生机制并提出治疗策略。
主要发现
- TAO高眼压的可能原因包括纤维化增大的直肌限制和压迫眼球、眶内淤血和静脉流出受阻导致巩膜表层静脉压升高、小梁流出阻力增加。
- 患者眼位和眼压测量仪器对眼压测量精准度也有较大影响。
- 极少数TAO患者合并原发性青光眼。
临床怎么用
- 作者提出应针对TAO的临床表现和特点制定不同的治疗策略以获得最佳临床疗效。
- 多数患者通过积极治疗TAO可使眼压降低;眼压无法降低者可考虑抗青光眼药物治疗;仅极少数青光眼病例需要抗青光眼药物或手术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with thyroid associated ophthalmopathy often have elevated intraocular pressure. Patients and doctors are often confused about whether intraocular hypertension in thyroid associated ophthalmopathy needs to be lowered. There are several theories on the possible causes of this kind of increased intraocular pressure: restriction and compression of the globe by fibrotic and enlarged rectus muscles, increased episcleral venous pressure resulting from orbital congestion and venous outflow obstruction, and increased resistance to trabecular outflow. In addition, the patient's eye position and the device for measuring intraocular pressure also have great impacts on the accuracy of intraocular pressure measurement. At the same time, there are very few patients with thyroid associated ophthalmopathy combined with primary glaucoma. Therefore, whether patients with elevated intraocular pressure need to be treated depends on the specific clinical manifestations of the thyroid associated ophthalmopathy. Intraocular pressure of most patients can be lowered by active treatment for thyroid associated ophthalmopathy; antiglaucoma medical therapy may be necessary for patients whose intraocular pressure cannot be lowered; only very few cases of glaucoma require antiglaucoma drugs or surgery. (Chin J Ophthalmol, 2019, 55:811-813). 甲状腺相关眼病(TAO)常伴发高眼压,发生机制复杂,包括肥大水肿的眼外肌压迫眼球壁;眶内结缔组织及眼肌肥大水肿使眶压增加,导致房水静脉压升高,房水流出阻力增加等。此外,测量眼压的眼位及使用的仪器对眼压测量的精准度也有较大影响。同时,极少数TAO患者合并原发性青光眼。TAO高眼压是否需要降眼压治疗,本文在分析高眼压发生机制的基础上,提出应针对TAO的临床表现和特点制定不同的治疗策略,以获得最佳临床疗效。(中华眼科杂志,2019,55:811-813).
引用
- Yang HS, Ye HJ. [Whether lowering intraocular pressure is needed for thyroid associated ophthalmopathy with intraocular hypertension]. Zhonghua Yan Ke Za Zhi. 2019. PMID: 31715677. doi:10.3760/cma.j.issn.0412-4081.2019.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。